Abstract: Joint tape 1 for attachment to a ceiling or a wall, the joint tape 1 comprising a layer of permeable non-woven material 2 and an adhesive layer 3 attached to the permeable non-woven material 2, the adhesive layer 3 being applied to one side of the non-woven material in a pattern comprising sections 21 without adhesive applied thereto and wherein the joint tape 1 has a width of 3 mm to 20 mm.

Abstract: Frieze tape (1) for attachment to a ceiling (10) or a wall, the frieze tape (1) comprising a layer of permeable non-woven material (2) and an adhesive layer (3) attached to the permeable non-woven material (2), the adhesive layer (3) being applied to one side of the non-woven material in a pattern comprising sections (21) without adhesive applied thereto.

Abstract: Method of attaching a lining 1 to an interior surface 10 of a room comprising the steps of: providing a first sheet of lining 1 to be applied to the interior surface 10; applying a plurality of glue dots 2 to the interior surface 10 or to the first sheet of lining 1; and attaching the first sheet of the lining 1 to the interior surface 10 such that the first sheet of lining 1 is fixed to the interior surface 10 via the glue dots.

Abstract: Sound-permeable lining (1) for covering perforations (21) shaped in an acoustic plasterboard (2). The sound-permeable lining (1) comprises a first ply (12) of a fleece material and attached thereto a second ply (14) which is arranged in between of the first ply (12) and the acoustic plasterboard (2) to which the sound-permeable lining (1) is to be applied. The second ply (14) being of a foil material having a second opacity O2 and a plurality of through-holes (141) formed therein. The first ply (12) has a first opacity O1 so that the through-holes (141) formed in the second ply (14) are invisible through the first ply (12) and so that the applied sound-permeable lining (1) has an overall opacity O12 to allow for optically covering the perforations (21) shaped in the acoustic plasterboard (2) and an overall air flow resistivity Rs12 to allow for the penetration of air so that sound can propagate via the sound-permeable lining (1).

Abstract: Sound-permeable lining (1) for covering perforations (21) shaped in an acoustic plasterboard (2). The sound-permeable lining (1) comprises a first ply (12) of a fleece material and attached thereto a second ply (14) which is arranged in between of the first ply (12) and the acoustic plasterboard (2) to which the sound-permeable lining (1) is to be applied. The second ply (14) being of a foil material having a second opacity O2 and a plurality of through-holes (141) formed therein. The first ply (12) has a first opacity O1 so that the through-holes (141) formed in the second ply (14) are invisible through the first ply (12) and so that the applied sound-permeable lining (1) has an overall opacity O12 to allow for optically covering the perforations (21) shaped in the acoustic plasterboard (2) and an overall air flow resistivity Rs12 to allow for the penetration of air so that sound can propagate via the sound-permeable lining (1).

Abstract: Compounds of general Formula I: wherein R1, R2, R3, x, A and Ra are as defined herein are inhibitors of cyclin-dependent kinases and are useful for preventing and/or treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

Abstract: Compounds of general formula (I): are useful as inhibitors of cyclin dependent kinases such as CDK9.

Abstract: A label laminate and a method for manufacturing a label laminate. The laminate includes a first label material layer and a second label material. The method includes forming a pattern in which adhesive areas and non-adhesive areas alternate on the face side of the first label material layer and on the face side of the second label material layer. The adhesive areas on the first label material layer are aligned with the non-adhesive areas on the second label material layer and the non-adhesive areas on the first label material layer are aligned with the adhesive areas on the second label material layer. The face sides of two label material layers are attached to each other. The adhesive areas are formed by a screening method. The non-adhesive areas have a surface energy, which is at least 25 dynes.

Abstract: are useful as inhibitors of cyclin dependent kinases such as CDK9.

Abstract: The present invention provides compositions and methods for treating pain using a compound of general Formula I: wherein the substituents thereof are as described herein.

Abstract: A label laminate and a method for manufacturing a label laminate. The laminate includes a first label material layer and a second label material. The method includes forming a pattern in which adhesive areas and non-adhesive areas alternate on the face side of the first label material layer and on the face side of the second label material layer. The adhesive areas on the first label material layer are aligned with the non-adhesive areas on the second label material layer and the non-adhesive areas on the first label material layer are aligned with the adhesive areas on the second label material layer. The face sides of two label material layers are attached to each other. The adhesive areas are formed by a screening method. The non-adhesive areas have a surface energy, which is at least 25 dynes.

Abstract: A non-human animal model is provided, particularly a mouse model for movement hyperactivity, excitoxicity disorders (e.g. myoclonic cramping) and neurodegeneration, in which modified cytoplasmic dynein heavy chain1 is expressed. Modified human and mouse cytoplasmic dynein heavy chain1 proteins and nucleic adds are also provided, including the corresponding recombinant proteins. The invention further provides uses for the non-human animal model and the modified cytoplasmic dynein heavy chain1 proteins and nucleic acids, in particular for the diagnosis and treatment of medical conditions associated with over-expression of cytoplasmic dynein heavy chain1.

Abstract: The present invention relates to a non-human vertebrate animal model displaying an alteration in fat metabolism or in the sensitivity towards leptin or insulin, which model bears a mutation in the gene encoding the spinster like 1 protein (Spinl1). The invention also relates to mutant Spinl1 proteins and nucleic acid sequences encoding these proteins. Furthermore, the invention relates to the use of the non-human vertebrate animal model for the identification of diagnostic markers, or as a model for studying the molecular and physiological mechanisms associated with an alteration in fat metabolism or an alteration in the sensitivity towards leptin or insulin, or for the identification and testing of agents useful in the prevention, amelioration, or treatment of the above conditions. Agents, pharmaceutical compositions, and methods for treating the above conditions are likewise described, as are methods for identifying said agents.